KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$12.17-4.92%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · KLRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers
KLRA — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi…
Why it matters: A timely start would keep the new tri-agonist plan on track. A delay would put the next pipeline step in doubt.
Supportive ifKailera starts its KAI-4729 Phase 1 trial by December 31, 2026.
Worry ifKailera has not started the trial by December 31, 2026, or reports a later start date.
Why it matters: Results will show whether higher doses can add weight loss. They will also test safety at those doses.
Watch forMid-2027 results show more weight loss at higher doses, plus safety and tolerance data.
Also watch forResults show little added weight loss at higher doses, troubling safety findings, or a delay past mid-2027.
Why it matters: The data will test whether the lower starting dose and slower dose steps help patients tolerate the drug.
Watch forKailera reports 2027 trial results on weight loss and how well patients tolerate the tested doses.
Also watch forKailera reports weak weight loss, poor tolerance, or a delay past 2027.
Why it matters: The company plans several large trials. A shorter cash runway could force changes to those plans.
Worry ifOn November 11, Kailera reports cash or spending that moves its stated runway earlier than mid-2028.
Less concerning ifKailera keeps its runway into mid-2028 and reports no cut or delay to planned trials.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$313 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $685 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,154 loss on $10,000 · 61.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.